INTRODUCTION {#S1}
============

T cell receptor (TCR) signaling in response to antigen recognition plays a key role in the immune response and is modulated by numerous viral pathogens ([@R25]). Remarkably, primate lentiviruses show fundamental differences in their effects on TCR signaling and T cell activation. Most simian immunodeficiency viruses (SIVs), as well as HIV-2 originating from SIV~smm~-infected sooty mangabeys, use the accessory protein Nef to remove the CD3 receptor from the cell surface ([@R5]; [@R23]; [@R58]). CD3 is a key component of the TCR complex and essential for intracellular signaling as well as cell surface expression of the TCR complex. Thus, primate lentiviruses capable of downmodulating CD3 prevent the formation of the immunological synapse between virally infected CD4^+^ T cells and antigen-presenting cells (APCs) and suppress T cell activation ([@R4]). In stark contrast, HIV-1 and its SIV precursors infecting chimpanzees and gorillas (SIV~cpz~ and SIV~gor~) entirely lost the CD3-TCR downmodulation function of Nef ([@R58]). Consequently, these viruses boost rather than prevent the responsiveness of infected CD4^+^ T cells to CD3-TCR-mediated stimulation by APCs ([@R4]; [@R16]; [@R17]). The loss of this Nef function in the primate lentiviral lineage that gave rise to HIV-1 was most likely facilitated by the acquisition of a *vpu* gene ([@R21]; [@R31]), because Vpu and Nef-mediated downmodulation of CD3 both suppress nuclear factor κB (NF-κB)-driven antiviral gene expression ([@R22]; [@R36]; [@R54]).

Lack of Nef-mediated CD3 downmodulation is associated with increased levels of activation, apoptosis, and expression of death receptors and inflammatory cytokines in virally infected cultures of human CD4^+^ T cells ([@R29]; [@R58], [@R59]). It has been hypothesized that primate lentiviruses boosting CD3-TCR signaling and CD4^+^ T cell activation might induce stronger immune responses than those preventing it ([@R31]). Indeed, chronic hyper-immune activation and high levels of apoptosis are hallmarks of pathogenic HIV-1 infection and absent in natural simian hosts of SIV that do not develop disease despite high levels of viral replication ([@R7]; [@R64]). In agreement with an increased virulence of primate lentiviruses lacking the CD3-TCR downmodulation function of Nef, SIV~cpz~ may cause an AIDS-like disease in wild chimpanzees ([@R27]). In addition, the low prevalence of other *vpu*-containing SIV strains(i.e., SIV~gsn~, SIV~mus~, and SIV~mon~) in their natural host species (i.e., greater spot-nosed monkeys, mustached guenons, and mona monkeys) suggests that these viruses may also cause disease in the wild ([@R60]). Finally, HIV-2 is less pathogenic in humans than HIV-1 ([@R40]), and the efficiency of Nef-mediated downmodulation of CD3 correlates with reduced immune activation and high CD4^+^ T cell counts in viremic HIV-2-infected individuals ([@R15]; [@R29]).

While several lines of evidence support a protective role against harmful hyper-immune activation, Nef-mediated down-modulation of CD3-TCR does not prevent AIDS progression in poorly adapted recent or experimental hosts of primate lentiviruses, such as humans or rhesus macaques, respectively. A variety of mechanisms might allow well-adapted natural simian hosts to avoid chronic immune activation and remain AIDS-free despite high virus replication ([@R33]; [@R47]; [@R48]). However, even in well-adapted species such as African green monkeys and sooty mangabeys, the CD3 downmodulation function of Nef seems to reduce immune activation ([@R26]) and protect against the loss of CD4^+^ T cells ([@R59]). It seems conceivable that both intrinsic susceptibility of the host to disease as well as specific viral properties determine the clinical outcome of infection. Understanding the viral determinants of immune activation and inflammation is important, since these events drive disease progression and favor HIV persistence ([@R41]). However, the potential importance of the loss of the CD3 downmodulation of Nef for the high virulence of HIV-1 has never been addressed in a disease susceptible host of primate lentiviruses. Here, we show that specific disruption of this Nef function is associated with increased acute inflammation and improved control of viral replication during the chronic phase of SIV~mac~ infection of rhesus macaques.

RESULTS {#S2}
=======

Specific Disruption of the CD3 Downmodulation Function of SIV~mac239~ Nef {#S3}
-------------------------------------------------------------------------

Given that primate lentiviral Nef proteins differ fundamentally in their ability to downmodulate CD3-TCR cell surface expression, it seemed paradoxical that this function maps to the highly conserved core region of otherwise highly variable primate lentiviral Nef proteins ([@R23]; [@R55]). Nef performs numerous activities ([@R35]; [@R52]), and for many years, it seemed impossible to disrupt the CD3 downmodulation function without affecting any other activity. Two recent advances allowed us to overcome this challenge. First, some rare, naturally occurring Nef variants in SIV~smm~-infected sooty mangabeys are defective in CD3 down-modulation but seemed otherwise fully functional ([@R59]; [@R62]). Second, recent analyses elucidated the structural basis for this Nef function and identified a hydrophobic cavity in the core domain of SIV~mac~ Nef that accommodates tyrosine-based motifs in the ζ chain of the CD3 complex for effective endocytosis ([@R30]; [@R39]). Together, these findings suggested that specific amino acid changes located at the rim of the hydrophobic pocket in the core region of Nef specifically affect CD3-TCR downmodulation. Based on these observations, we introduced three amino acid changes (I123L, L146F and D158N) that naturally occurred in some SIV~smm~ strains, individually and in combination, into the core region of SIV~mac239~ Nef ([Figure 1A](#F1){ref-type="fig"}). All mutant Nefs were efficiently expressed ([Figure 1B](#F1){ref-type="fig"}), and combined changes of I123L and L146F disrupted the effect of SIV~mac239~ Nef on CD3 cell-surface expression without reducing its ability to downmodulate CD4, major histocompatibility complex (MHC) class I, CXCR4, or CD28 ([Figures 1C](#F1){ref-type="fig"} and [S1](#SD1){ref-type="supplementary-material"}). In addition, all Nef mutants were fully active in enhancing virion infectivity ([Figure 1D](#F1){ref-type="fig"}) and promoting viral replication in human peripheral blood mononuclear cells (PBMCs) ([Figure 1E](#F1){ref-type="fig"}). Just like HIV-1 Nef, however, mutant SIV~mac239~ Nefs lacking the CD3 downmodulation function lost the ability to block T cell activation ([Figure 1F](#F1){ref-type="fig"}). Altogether, our results demonstrated that combined mutations of I123L and L146F specifically disrupt the effect of SIV~mac239~ Nef on CD3, mimicking the loss of this Nef function in the SIV precursors of HIV-1.

Nef-Mediated CD3 Downmodulation Is Critical for Maintenance of High Viral Loads {#S4}
-------------------------------------------------------------------------------

Asian macaques are highly susceptible to virus-induced immunodeficiency ([@R14]), and experimental infection of rhesus macaques with SIV~mac~ is perhaps the best-characterized and most widely used non-human primate model for studies of AIDS pathogenesis, prevention, and therapy ([@R18]). Pioneering studies in the SIV/macaque model demonstrated that Nef is critical for efficient viral replication and full pathogenic potential ([@R28]) and *nef*-deleted viruses were candidates for live-attenuated vaccine development ([@R9]). This animal model also revealed strong selective pressure for intact functional *nef* genes *in vivo* ([@R28]). In addition, infection with mutant forms of SIV~mac239~ provided insights into the relevance of specific Nef functions, such as downmodulation of the CD4 receptor or MHC class I molecules, for viral immune evasion and replication fitness ([@R6]; [@R43]; [@R57]; [@R69]). For our *in vivo* studies, we used an SIV~mac239~ construct expressing a triple mutant Nef (referred to as CD3ko-Nef) containing the I123L and L146F changes that disrupt the effect on CD3 and a D158N substitution. The latter had no significant effect on Nef function ([Figures 1C](#F1){ref-type="fig"}--[1F](#F1){ref-type="fig"}) but was included as neutral control to better assess selective pressures on Nef and the occurrence of reversions *in vivo*.

Infection of 12 rhesus macaques with the wild-type (WT) and CD3ko-Nef SIV~mac239~ constructs (six animals each) showed that lack of CD3-TCR downmodulation of Nef has little if any effect on the kinetics and efficiency of viral replication during acute infection ([Figure 2A](#F2){ref-type="fig"}, left). Starting from week 6, however, the virological outcome of infection diverged substantially. All six WT SIV~mac239~-infected rhesus macaques maintained plasma viral RNA loads ranging from \~10^5^ to \~10^6^ copies/mL during chronic infection ([Figure 2A](#F2){ref-type="fig"}, middle). In contrast, the levels of viremia were highly diverse in animals infected with the CD3ko-Nef SIV~mac239~ construct ranging from undetectable (i.e., ≤ 40 copies/mL) to almost 10^8^ viral RNA copies/mL plasma ([Figure 2A](#F2){ref-type="fig"}, right).

To define the reasons for these striking differences, we examined reversions and potential compensatory changes in *nef* from plasma viral RNA ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2B](#SD1){ref-type="supplementary-material"}). Our analyses revealed that the I123L and L146F mutations in Nef rapidly reverted between 6 and 12 weeks in animals 2503, 2583, and 2746, indicating significant selective pressure for the CD3-TCR downmodulation function ([Figure 2B](#F2){ref-type="fig"}). These three rhesus macaques showed very high levels of plasma viremia and cell-associated viral loads between 8 and 24 weeks post-infection (pi) ([Figures 2C](#F2){ref-type="fig"}--[2F](#F2){ref-type="fig"}). In contrast, viral replication was better controlled in animals showing slow reversion (15899 and 15926) and became undetectable in the absence of reversion (14875) ([Figures 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}). Several additional amino acid changes were observed in Nef proteins from animals 15899 and 15926, including R11K, R30K, and S240T. At the experimentally mutated positions, alterations of I123V and L146C emerged in animal 15899, while in animal 15926, only the L146F and not the I123L mutation reverted ([Figure S2B](#SD1){ref-type="supplementary-material"}). Functional analyses showed that these alterations largely restored the ability of Nef to downmodulate sCD3-TCR during later stages of infection ([Figure S2C](#SD1){ref-type="supplementary-material"}). Compared to WT SIV~mac239~-infected animals, the average viral RNA loads after the acute phase (i.e., from 8 to 24 weeks pi) were 13.2-fold higher in the presence but 26.3-fold lower in the absence of reversions. In addition, lack of reversion was associated with a drop in cell-associated viral loads by approximately two orders of magnitude ([Figures 2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}). At later stages of infection (≥32 weeks pi), the average levels of viremia were similar in all three groups ([Figure 2D](#F2){ref-type="fig"}). Reasons for this are the death of rapid progressors with high viral loads and the reversion of most CD3ko-Nef SIV~mac239~ constructs to the parental phenotype by that time. Altogether, our results indicate that Nef's ability of downmodulate CD3-TCR does not affect viral replication fitness during acute infection but is critical for the maintenance of high viral loads at later stages.

Lack of CD3 Downmodulation Increases Acute Immune Activation {#S5}
------------------------------------------------------------

To determine whether lack of Nef-mediated CD3-TCR downmodulation affects the immunological response to infection, we performed RNA sequencing (RNA-seq) and cytokine array analyses of PBMCs, lymph nodes, and plasma samples, respectively. Peak levels of plasma viremia were observed at 2 weeks pi and were highly similar in WT and CD3ko-Nef SIV~mac239~ infection (29.5 × 10^6^ ± 8.5 × 10^6^ versus 22.2 × 10^6^ ± 7.1 × 10^6^; mean viral RNA (vRNA) copies/mL ± SEM; [Figure 2A](#F2){ref-type="fig"}). The average cell-associated viral loads in both groups were identical at this time point ([Figure 2F](#F2){ref-type="fig"}), and reversions in *nef* were only detected several weeks later ([Figure 2B](#F2){ref-type="fig"}). Thus, WT and CD3ko-Nef SIV~mac239~ constructs showed almost equal replication fitness during acute infection ensuring that potential differences in parameters such as immune activation were due to distinct viral properties and not differences in viral loads.

BioCarta, KEGG, and Hallmark gene set enrichment analyses (GSEAs) demonstrated that Nef-mediated downmodulation of CD3-TCR inhibits the induction of pathways involved in innate and adaptive immunity, including "inflammatory response", interleukin-1R (IL-1R), IL-17, IL-6, and Toll-like receptor (TLR) signaling as well as "antigen processing and MHC-I presentation" and "complement activation" ([Figure 3A](#F3){ref-type="fig"}). In agreement with data obtained in cell culture ([@R29]; [@R59]), genes involved in NFAT and NF-κB signaling pathways were expressed at lower levels in the WT compared to the CD3ko-Nef samples. Thus, some immunosuppressive effects of Nef-mediated downmodulation of CD3-TCR may depend on reduced activity of these transcription factors.

At peak viremia (2 weeks pi), proinflammatory genes ([Table S1](#SD2){ref-type="supplementary-material"}) that are induced by TCR-CD3 stimulation in human PBMCs ([@R42]) were strongly enriched in animals infected with the CD3ko-Nef SIV~mac239~ construct compared to WT-infected animals ([Figure 3B](#F3){ref-type="fig"}). This was the case for both lymph nodes and PBMCs. In particular, the expression of pentraxin-3 (PTX3), reported to regulate the inflammatory activity of macrophages ([@R63]), as well as IL-6 and IP-10/CXCL10, known indicators of the inflammatory status in HIV infection ([@R10]), was higher in the lymph nodes of animals infected with the mutant virus than in those infected with WT SIV~mac239~ ([Figure 3B](#F3){ref-type="fig"}). In agreement with increased immune activation, lack of Nef-mediated downmodulation of CD3-TCR was associated with strong enrichment of genes encoding restriction factors ([@R36]). Among them were many interferon (IFN)-stimulated genes (ISGs), including members of the IFIT (IFN-induced proteins with tetratricopeptide repeats) and IFITM (IFN-induced transmembrane proteins) families, ISG15, OAS1, MX1, MX2, tetherin (BST2), and IFI16 ([Figure 3C](#F3){ref-type="fig"}). In addition, genes encoding, for example, APOBEC3 (apolipoprotein B mRNA editing enzyme catalytic polypeptide 3) family members, SLFN11, and SAMHD1 were enriched in CD3ko-Nef versus WT SIV~mac239~ infection ([Figure 3C](#F3){ref-type="fig"}). In agreement, with the proposed role of Nef-mediated downmodulation of CD3-TCR in suppressing NF-κB activity ([@R21]), lack of this Nef function was associated with enrichment of NF-κB target genes ([Table S1](#SD2){ref-type="supplementary-material"}) in lymph nodes and PBMCs ([Figure S3A](#SD1){ref-type="supplementary-material"}). The TLR pathway was also among the top gene sets enriched in the CD3ko-Nef group compared to the WT group of animals ([Figure 3A](#F3){ref-type="fig"}) and substantially more strongly induced in the former group during acute infection ([Figure S3B](#SD1){ref-type="supplementary-material"}).

Cytokine arrays confirmed increased induction of type I IFNs and other proinflammatory cytokines in the CD3ko-Nef compared to the WT group at 2 weeks pi, although the levels varied between individual animals ([Figures 4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}). Normalized for vRNA loads at 2 weeks pi, the average levels of various proinflammatory cytokines were increased between 1.8- and 6.9-fold in the CD3ko-Nef group ([Figures 4B](#F4){ref-type="fig"} and [S4A](#SD1){ref-type="supplementary-material"}). Examination of the RNA-seq data revealed that the differences between the CD3ko-Nef and WT groups, especially in type I IFN induction, were substantially more pronounced in the lymph nodes than in blood PBMCs ([Figure 4C](#F4){ref-type="fig"}). In line with this, several immune factors were induced to significantly higher levels by the CD3ko-Nef SIV~mac239~ construct in lymph nodes, but not in PBMCs ([Figure S4B](#SD1){ref-type="supplementary-material"}). These included IFN regulatory factor 5 (IRF5), a key regulator of inflammation involved in the induction of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α), IL-6, IL-12, and type I IFNs ([@R2]); CSF2RB, a common subunit of the granulocyte macrophage colony-stimulating factor (GM-CSF), IL-3, and IL-5 receptors ([@R45]); and the E3 ubiquitin-protein ligase MARCH1, reported to inhibit HIV-1 ([@R73]). Altogether, our results indicate that lack of Nef-mediated CD3 downmodulation in virally infected CD4^+^ T cells increases the levels of acute systemic immune activation and inflammation.

Impact of Nef-Mediated CD3 Modulation on Clinical Outcome and Adaptive Immunity {#S6}
-------------------------------------------------------------------------------

Rhesus macaques are highly susceptible to SIV-induced disease, and five of the six animals infected with WT SIV~mac239~ developed simian AIDS and had to be euthanized within 80 weeks of follow-up ([Table 1](#T1){ref-type="table"}; [Figure 5A](#F5){ref-type="fig"}). In contrast, the rates of clinical progression were highly diverse in macaques infected with the CD3ko-Nef SIV~mac239~ construct. In agreement with the development of high viral loads, rapid restoration of the CD3 downmodulation function of Nef in animals 2503, 2583, and 2746 was associated with progression to fatal simian AIDS by 23, 45, and 73 weeks pi ([Table 1](#T1){ref-type="table"}; [Figure 5A](#F5){ref-type="fig"}). In contrast, the absence of reversions in animal 14875 was associated with undetectable viral loads and lack of disease progression ([Table 1](#T1){ref-type="table"}). Similarly, animal 15926 remained clinically healthy during 88 weeks of follow-up, although partial reversion \~1 year after infection coincided with increasing viral loads and mild immune activation ([Figure 2A](#F2){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). Finally, complete reversion between weeks 37 and 57 in animal 15899 was associated with increasing viral loads and development of simian AIDS by the end of the study at 81 weeks pi. The total percentage of CD4^+^ T cells in blood decreased with similar kinetics in CD3ko-Nef and WT SIV~mac239~-infected animals and differed moderately between the rapid and slow/no reversion CD3ko-Nef groups ([Figure 5B](#F5){ref-type="fig"}). In comparison, the numbers of CCR5^+^/CD4^+^ T cells declined rapidly in most infected animals, but this decline was more pronounced in animals showing rapid reversion of Nef function in the CD3ko-Nef group ([Figure 5C](#F5){ref-type="fig"}).

Together, these results suggested a role of Nef-mediated CD3-TCR downmodulation in viral immune evasion during chronic infection. To obtain further insights into the underlying mechanisms, we investigated the virus-specific cellular response to three different viral peptide pools and whole chemically inactivated SIV~mac251~ particles (SIV AT-2) by IFN-γ ELISpot and the humoral response to the SIV core protein p27 and the Env protein gp130 by ELISA. All nine animals infected with the parental SIV~mac239~ construct or showing rapid reversion after infection with the CD3ko-Nef derivative showed only transient CD4^+^ T cell responses against SIV AT-2 during the early phase of infection ([Figure 5D](#F5){ref-type="fig"}). In contrast, persisting responses were observed in the three rhesus macaques of the no/slow reversion group. Conversely, CD8^+^ T-cell-mediated Gag responses were variable in macaques infected with WT SIV~mac239~ and generally weak or absent in animals that received the CD3ko-Nef mutant virus ([Figure 5E](#F5){ref-type="fig"}). The exception in the latter group was animal 14875 that controlled viral replication in the absence of reversions and developed a robust Gag response ([Figure 5E](#F5){ref-type="fig"}). Significant ELISpot responses to Tat were only detected in the WT-infected animal 15925 ([Figure S5A](#SD1){ref-type="supplementary-material"}), while Nef responses were observed in the three WT SIV~mac239~-infected animals showing relatively slow disease progression and all three no/slow reverters of the CD3ko group ([Figure S5B](#SD1){ref-type="supplementary-material"}). The levels of activated/proliferating CD4^+^ and CD8^+^ lymphocyte subsets varied between individual animals and did usually not differ significantly between the WT and CD3ko groups of SIV~mac239~-infected animals ([Figure S5C](#SD1){ref-type="supplementary-material"}). Altogether, only the slow/non-progressor CD3ko group showed persistent, largely CD4^+^ T-cell-mediated ([@R51]), IFN-γ responses to whole SIV antigen, while the Gag-specific CD8^+^ T-cell-mediated responses appeared to be more prevalent in animals infected with WT SIV~mac239~.

The percentages of B cells secreting Env-specific antibodies varied strongly within each group ([Figure 5F](#F5){ref-type="fig"}). However, animals showing relatively slow clinical progression after WT or CD3ko-Nef SIV~mac239~ infection displayed higher levels of B cell activation than those that progressed to simian AIDS within the first year after infection ([Figure S5D](#SD1){ref-type="supplementary-material"}, left). At 1 and 2 weeks pi, B cells expressing the CD80 activation marker were more strongly induced in CD3ko-Nef than in WT SIV~mac239~ infection ([Figure S5D](#SD1){ref-type="supplementary-material"}, right). Most infected animals showed efficient and persistent humoral immune responses against the gp130 Env glycoprotein ([Figure 5G](#F5){ref-type="fig"}). The exception was animal 15934 showing rapid disease progression after WT SIV ~mac239~ infection ([Table 1](#T1){ref-type="table"}). In comparison, the humoral response against the p27 capsid antigen was highly diverse ([Figure 5H](#F5){ref-type="fig"}). The three animals showing rapid disease progression after WT SIV ~mac239~ infection displayed weak anti-p27 antibody (Ab) responses during both the acute and chronic infection. The three rapid reverters in the CD3ko group also showed weak anti-p27 Ab responses during chronic infection, although two of them (2503 and 2583) showed high reactivity during acute infection ([Figure 5H](#F5){ref-type="fig"}). Vice versa, slow/no reversion was associated with the maintenance of high and stable anti-p27 Ab responses despite delayed and weaker reaction of two macaques (15926 and 15899) during acute infection. Thus, while the titers against gp130 Env were similar in all groups, efficient controllers had higher antibody titers against p27 than progressors, and these titers remained stable in the absence of Nef-mediated downmodulation of the TCR-CD3 receptor.

DISCUSSION {#S7}
==========

Previous studies have shown that primate lentiviral Nef proteins differ fundamentally in their effect on CD3-TCR signaling and T cell activation. Nef proteins of HIV-1 and its precursors, SIV~cpz~, SIV~gor~, and SIV~gsn/mus/mon~, enhance the responsiveness of virally infected T cells to CD3-TCR-mediated stimulation ([@R16]; [@R17]; [@R58]; [@R71]). In contrast, Nef proteins of most SIVs and HIV-2 efficiently prevent T cell activation by removing the CD3-TCR complex from the cell surface ([@R5]; [@R29]; [@R58]; [@R61]). Boosting or suppressing T cell activation may both be advantageous for primate lentiviruses depending on the immunological microenvironment. On the one hand, activated CD4^+^ T cells are the main targets for viral replication; thus, the virus may enhance CD3-TCR signaling to render infected T cells fully permissive for viral infection and spread. On the other hand, CD3-TCR signaling is also critical for the ability of helper CD4^+^ T cells to interact with APCs and initiate immune effector functions such as cytokine production and cytotoxicity. In the present study, we determined the impact of Nef-mediated downmodulation of CD3 on the virological, immunological, and clinical outcome of primate lentiviral infection in rhesus macaques that are highly susceptible to SIV-induced disease. We show that loss of the CD3 downmodulation function of Nef is associated with an increased acute inflammatory response to SIV infection, particularly in lymph nodes. In support of a key role in viral immune evasion, reversions in Nef that restored its ability to downmodulate CD3 coincided with the maintenance of high viral loads during chronic infection.

HIV and SIV Nef proteins perform a striking variety of functions, and dissecting their relative importance for viral fitness and pathogenicity *in vivo* requires the selectively disruption of individual activities. This task was particularly challenging for the CD3 downmodulation function, since it maps to the highly conserved core domain of Nef and active and inactive forms do not show definitive differences ([@R23]; [@R55]). While it was never possible to selectively disrupt this Nef function experimentally, the ability of lentiviruses to adapt to their host environment achieved this. Specifically, highly unusual CXCR4-tropic SIV~smm~ strains that emerged in sooty mangabeys selectively lost the CD3 downmodulation activity of Nef ([@R59]), most likely because this activity is not advantageous in naive CXCR4^+^ T cells ([@R62]). Here, we show that the I123L and L146F changes that emerged *in vivo* and disrupted the interaction of SIV~smm~ Nef with the CD3 ζ chain also specifically disrupt the CD3 downmodulation function of SIV~mac239~ Nef ([Figure 1](#F1){ref-type="fig"}). Generation of this mutant Nef SIV~mac239~ construct allowed us to directly explore the role of Nef-mediated CD3-TCR downmodulation in primate lentivirus-mediated immune activation and pathogenesis in rhesus macaques that are highly susceptible to AIDS-like disease.

During the acute phase of infection, the CD3ko-Nef SIV~mac239~ replicated with kinetics and efficiencies that were undistinguishable from the parental virus ([Figure 2A](#F2){ref-type="fig"}). In comparison, acute peak viral loads are usually reduced by more than two orders of magnitude upon complete deletion of *nef* in SIV~mac239~ ([@R24]). Equal early replication fitness together with absence of reversions during acute infection allowed meaningful comparison of the immune activating properties of the CD3ko-Nef mutant and parental SIV~mac239~ strains. We found that lack of Nef-mediated CD3-TCR downmodulation further increased immune activation and the inflammatory response to infection, particularly in lymphoid tissues, confirming our hypothesis that this Nef function reduces the prevailing levels of SIV-associated immune activation. Nef-mediated downmodulation of CD3 was associated with decreased expression of restriction factors ([Figure 3C](#F3){ref-type="fig"}) and NF-κB target genes ([Figure S3A](#SD1){ref-type="supplementary-material"}). This agrees with the evidence that Nef-mediated downmodulation of CD3-TCR and Vpu-dependent suppression of nuclear p65 translocation represent alternative strategies to suppress NF-κB-dependent immune activation and antiviral gene expression ([@R21]). It is thought that CD4^+^ helper T cells are most important for the adaptive immune response, i.e., efficient humoral responses and the activation of cytotoxic T lymphocytes (CTL). Thus, it is noteworthy that lack of Nef-mediated downmodulation of CD3 in infected CD4^+^ T cells was associated with increased type I IFN induction ([Figure 4](#F4){ref-type="fig"}) and enhanced expression of proteins involved in TLR signaling ([Figure S3B](#SD1){ref-type="supplementary-material"}), supporting a role of CD3-TCR signaling in viral immune sensing and innate immune activation. It may seem surprising that animals infected with WT and CD3ko SIV~mac239~ constructs showed similar viral loads, although the latter induced strong innate immune responses. However, infected primary CD4^+^ T cells maintaining CD3 expression show higher levels of activation and viral gene expression ([@R72]). In addition, recent data show that lack of Nef-mediated downmodulation of CD3 is associated with increased cell-to-cell spread (Dejan Mesner and Prof. Dr. Clare Jolly, personal communication). These mechanisms might compensate for improved immune control during acute infection.

The presence or absence of reversions in Nef that restored the CD3 downmodulation function was associated with strikingly different outcomes of infection. Lack of reversions in animal 14875 was associated with efficient control of viral replication ([Figure 2](#F2){ref-type="fig"}) and absence of disease progression ([Table 1](#T1){ref-type="table"}). Late reversions in macaques 15926 and 15899 were associated with increases in viral loads and slow disease progression. Surprisingly, the set-point viral loads in the three animals showing rapid reversion to a fully functional Nef were on average more than 10-fold higher compared to the six macaques infected with WT SIV~mac239~, and all these animals progressed to simian AIDS during follow-up. One possible reason for this is that an increased acute inflammatory response provides more activated CD4^+^ T cell targets for viral replication. Notably, it has been reported that the levels of immune activation early in HIV-1 infection are positively associated with viremia and determine the rate of CD4^+^ T cell loss in untreated individuals ([@R11]). In strict contrast, macaques showing no/slow restoration of the CD3 downmodulation function of Nef had \~350-fold lower set-point viral loads than rapid reverters ([Figure 2D](#F2){ref-type="fig"}). Effective replication of the CD3ko SIV~mac239~ construct during acute infection suggests that the low levels of viremia at later stages are immune mediated rather than due to intrinsic differences in replicative capacity. In fact, no/slow reverters showed significantly stronger IFN-γ responses to whole SIV antigen ([Figure 5D](#F5){ref-type="fig"}) and had higher antibody titers against p27 ([Figure 5H](#F5){ref-type="fig"}) than rapid reverters. More comprehensive studies are required to fully define the mechanisms underlying effective immune control in the absence of Nef-mediated downmodulation of CD3, but our preliminary data suggest that lack of this Nef function is associated with stronger CD4^+^ T cells responses.

A role of CD3 downmodulation in both viral pathogenesis and immune evasion agrees with early findings that chimeric SIV~mac239~ constructs expressing HIV-1 *nef* genes frequently result in an "all or nothing" phenotype, i.e., high viral loads and rapid disease progression or effective control of the chimeric viruses ([@R1]; [@R32]; [@R38]). In agreement with the present data, SIV~agm~ constructs expressing an HIV-1 *nef* gene showed high levels of replication during acute infection but were subsequently better controlled by the immune system than the parental SIV~agm~ construct expressing a Nef that downmodulates CD3-TCR ([@R26]). In these experiments, insertion of a functional *vpu* gene into the SIV~agm~ genome in addition to the HIV-1 *nef* gene was associated with \~20-fold higher viral loads during chronic infection. Thus, Vpu may functionally compensate for the lack of the CD3 down-modulation function of Nef. Altogether, our results further support that enhanced immune activation and type I IFN induction may have both beneficial and detrimental effects ([@R70]), the former if leading to effective control of virus replication and the latter if the virus is capable of efficiently evading immune control and using the increased availability of activated CD4^+^ target T cells to its advantage.

In summary, we show for the first time that specific disruption of the CD3 downmodulation function of Nef that was lost by HIV-1 and its SIV precursors but is otherwise highly conserved among primate lentiviruses affects the systemic acute immune response and the virological and clinical outcomes of SIV~mac~ infection in rhesus macaques. Specifically, our data demonstrate that lack of CD3-TCR downmodulation in SIV-infected cells clearly increases inflammation and immune activation *in vivo*. Our results further suggest that the CD3-TCR downmodulation function of Nef is essential for efficient viral immune evasion and maintenance of high viral loads in primate lentiviruses lacking a *vpu* gene.

STAR★METHODS {#S8}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S9}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Frank Kirchhoff (<frank.kirchhoff@uni-ulm.de>). All unique/stable reagents generated in this study are available from the Lead Contact without restriction.
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### Ethical statement for human samples {#S11}

Experiments involving human blood and CD4+ T cells were reviewed and approved by the Institutional Review Board (i.e., the Ethics Committee of Ulm University). Individuals and/or their legal guardians provided written informed consent prior to donating blood. All human-derived samples were anonymized before use. The use of established cell lines (HEK293T, Jukat and P4-CCR5 cells) did not require the approval of the Institutional Review Board.

### Ethical statement for animal experiments {#S12}

Nine male and three female purpose-bred rhesus macaques (*Macaca mulatta*) that were 4.5--5.5 years old when allocated to the experiment were obtained from the German Primate Center (DPZ) breeding colony. Animals from this study were cared for by qualified staff of the DPZ and housed according to the German Animal Welfare Act which complies with the European Union guidelines on the use of non-human primates for biomedical research and the Weatherall report. The study was approved by the Lower Saxony State Office for Consumer Protection and Food Safety and performed with the project licenses 33.19-42502-04-12/0758 and 33.19-42502-04-15/2001. The DPZ has the permission to breed and house non-human primates under license number 392001/7 granted by the local veterinary office and conforming with § 11 of the German Animal Welfare act. Socially compatible monkeys were housed in groups of two by combining cages. If animals had to be caged individually they had constant visual, olfactory and acoustic contact to their roommates and could still groom their neighbors through small mash inserts in the separating side walls. Each cage was equipped with a perch. The animals had water access *ad libitum* and were fed with dry monkey biscuits containing adequate carbohydrate, energy, fat, fiber (10%), mineral, protein, and vitamin content twice daily. The feed was supplemented by fresh fruit or vegetables and other edible objects like nuts, cereal pulp and different seeds to offer variety to the diet. Moreover, for environmental enrichment monkeys were provided feeding puzzles boards, alternate toys and wood sticks for gnawing. During the study, animals were assessed by experienced keepers twice a day for any signs of distress, pain or sickness by checking water and feed intake, feces consistency and the general condition. In case of any abnormal presentation, animals were attended by veterinarians.

### Cell lines {#S13}

Human Embryonic Kidney (HEK) 293T cells ([@R13]) were obtained from the American Type Culture Collection (ATCC). P4-CCR5 reporter cells were kindly provided through the NIH AIDS Reagent Program. Both cell lines were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin. P4-CCR5 cells express CD4, CCR5 and CXCR4 and contain the β-galactosidase genes under the control of the HIV-1 promoter ([@R8]). Jurkat-NFAT cells contain a luciferase gene under the control of the NFAT promoter ([@R17]) and were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine, 100 units/ml penicillin, 120 μg/ml streptomycin and 200 μg/ml G418 (geneticin). Jurkat-NFAT cells were transduced with eGFP-reporter proviral constructs and stimulated with 4 mg/ml PHA for 16 hr before lysis and determination of luciferase activity.

### Primary cell culture {#S14}

Peripheral blood mononuclear cells (PBMCs) from healthy human donors were isolated using lymphocyte separation medium (Biocoll separating solution; Biochrom), stimulated for 3 days with phytohemagglutinin (PHA; 2 μg/ml), and cultured in RPMI 1640 medium with 10% fetal calf serum and 10 ng/ml interleukin-2 (IL-2) prior to infection or first infected and then cultured in medium only until stimulation with PHA at day 3 or 6. CD4+ T cells from healthy human donors were isolated using RosetteSep Human CD4+ T Cell Enrichment Cocktail (Stemcell) and lymphocyte separation medium (Biocoll separating solution; Biochrom), stimulated for 3 days with PHA (2 μg/ml), and cultured in RPMI 1640 medium with 10% FCS and 10 ng/ml interleukin-2 (IL-2) prior to infection.

METHOD DETAILS {#S15}
--------------

### Proviral constructs {#S16}

Proviral HIV-1 NL4--3-IRES-eGFP constructs containing an internal ribosome entry site (IRES) and encoding the enhanced version of the green fluorescent protein (eGFP) were generated as described ([@R56]). Overlap-extension PCR was used to replace the NL4--3 *nef* in wt or IRES-eGFP HIV-1 constructs by wt or mutant SIV~mac239~ *nef* genes as described ([@R58]). The integrity of all PCR-derived inserts was confirmed by sequencing. The control HIV-1 NL4--3-IRES-eGFP constructs expressing the NL4--3, NA7, and SIV~mac239~ Nefs or containing a deleted (*Δnef*) or disrupted (*nef*\*) *nef* gene have been reported previously ([@R44]).

### Expression vectors {#S17}

Cloning of *nef* alleles into the bi-cistronic CMV promoter-based pCG expression vector co-expressing the enhanced green fluorescent protein (eGFP) was described previously ([@R58]). In brief, *nef* genes were amplified by PCR with flanking primers introducing a C-terminal AU1 tag and XbaI and MluI restriction sites for cloning into the pCG IRES eGFP vector.

### Western blot {#S18}

To examine the expression of primate lentiviral Nef proteins, HEK293T cells were transfected in 6-well dishes with 5 μg DNA of pCG IRES eGFP vectors expressing AU1-tagged Nefs. Two days post-transfection, cells were lysed with Co-IP buffer (150 mM NaCl, 50 mM HEPES, 5 mM EDTA, 0.1% NP40, 0.5 mM sodium orthovanadate, 0.5 mM NaF, protease inhibitor cocktail from Roche, pH 7.5) and reduced in the presence of β-mercaptoethanol by boiling at 95°C for 10 min. Proteins were separated in 4 to 12% Bis-Tris gradient acrylamide gels (Invitrogen), blotted onto polyvinylidene difluoride (PVDF) membrane, and incubated with anti-AU1 (MMS-130P; Covance), anti-GFP (ab290; Abcam), and anti-β-actin (ab8227; Abcam) antibodies.

### Flow cytometry {#S19}

To analyze Nef function, CD4, MHC-I, CD28, CD3, CXCR4 and tetherin surface levels in PBMCs or CD4+ T cells transduced with HIV-1 NL4--3 constructs coexpressing Nef and GFP or containing a disrupted *nef* gene as control were measured as described previously ([@R53]; [@R58]). Briefly, the cells were washed and stained with fluorescently labeled antibodies. Staining was performed for 30 to 60 min at 4°C. After fixing the cells with 2% PFA, measurement was performed using a BD FACSCanto II. For flow cytometry, the following antibodies were titrated and validated using matching isotype controls from the same supplier: anti-human CD3 (1:40, SP34--2, BD, Cat\# 557749 or 1:5, UCHT1, BD, Cat\# 555335), anti-human CD4 (1:20, L200, BD, Cat\# 560811 or 1:5, RPA-T4, BD, Cat\# 555349), anti-human MHC-I (1:20, G46--2.6, BD, Cat\# 561346), anti-human CXCR4 (1:40, 12G5, BD, Cat\# 560670), anti-human CD28 (1:10, CD28.2, BD, Cat\# 559770 or 1:20, CD28.2, BD, Cat\# 560684) and anti-human tetherin (1:20, RS38E, BioLegend, Cat\# 348410).

For analysis of rhesus macaque cells, 50 μL of whole blood were stained for 30 min at RT in the dark with different mixtures of monoclonal antibodies (mAb) directed against CD3 (clone SP34--2, Alexa Fluor 700), CD4 (clone L200; Horizon V450), CD45 (clone D058--1283, Horizon V500), CD80 (clone L307.4, PE) and CD195 (clone 3A9, PE), all from BD Biosciences, Heidelberg, Germany; CD8 (clone 3B5, Pacific Orange, Invitrogen, Carlsbad, USA, due to adjustment in the staining protocol replaced by CD8 (clone RPA-T8, PerCP-Cy5.5; for animals 2729, 2746, 15899, 15925, 15926), CD20 (clone 2H7, PE-Cy7), CD25 (clone M-A251, APC-Cy7, replaced by APC-Fire for above mentioned animals), HLA-DR (clone L243, APC-Cy7) all from BioLegend, San Diego, USA as well as CD69 (clone TP1.55.3, ECD) Beckman Coulter, Krefeld, Germany. Lysis of residual RBCs (red blood cells) and fixation was performed by subsequent incubation with 1 mL RBC lysis/fixation solution from BioLegend for 15 min. Following a washing step with staining buffer (phosphate-buffered saline with 5% bovine serum albumin) cells were acquired using a LSRII cytometer (BD Biosciences). Data analysis was performed using FlowJo 9.6.4 (Treestar, Ashland, OR, USA).

### Virus stocks and transductions {#S20}

To generate virus stocks, HEK293T cells were co-transfected with the proviral HIV-1 or SIVmac constructs alone (for assays on infectivity and replication) or together with a plasmid (pHIT-G) expressing the vesicular stomatitis virus G protein (VSV-G) to achieve comparably high initial infection levels for flow-cytometric analyses. Two days post-transfection, supernatants containing infectious virus was harvested. The amount of HIV-1 capsid protein was quantified by p24 antigen ELISA as described ([@R34]) for normalization of the virus dose. CD4+ T cells, PBMCs or Jurkat cells were transduced with VSV-G pseudotyped virus stocks containing normalized quantities of p24 antigen. Four hours post-transduction, cells were washed three times in PBS, resuspended in RPMI 1640 medium with 10% heat-inactivated FCS, 2 mM L-glutamine and antibiotics and cultured for two to three days prior to flow cytometric analysis.

### Viral infectivity {#S21}

Virus infectivity was determined using P4-CCR5 as described ([@R44]). Briefly, the cells were sown out in 96-well dishes in a volume of 100 μL and infected by overnight incubation with virus stocks, containing 1 ng of p24 antigen, produced by transfected HEK293T cells. Three days post-infection, viral infectivity was detected using the Gal-Screen kit from Applied Biosystems as recommended by the manufacturer. β-galactosidase activity was quantified as relative light units per second using the Orion microplate luminometer.

### NF-AT assay {#S22}

Jurkat cells stably transfected with an NF-AT-dependent reporter gene vector ([@R17]) were either left uninfected or transduced with HIV-1 IRES eGFP constructs expressing various *nef* alleles. Except for those cells used as controls, cultures were treated with PHA (4 μg/ml; Murex). Luciferase activity was measured and n-fold induction determined by calculating the ratio of measured relative light units (RLU) of treated samples to that of untreated samples, as described previously ([@R29]).

### Experimental animals, virus inoculation and specimen collection {#S23}

Twelve purpose-bred young adult rhesus macaque, 9 males and 3 females, were obtained from the DPZ breeding colony. When allocated to the experiment, they were 4.5--5.5 years old with a bodyweight between 4.7--8.9 kg. All monkeys were seronegative for Simian Retrovirus Typ D, Simian Immunodeficiency Virus, and Simian T-lymphotropic Virus. Animals were randomly distributed to two groups with six monkeys each. For blood collection from the femoral vein by using the vacutainer system (BD), animals were anesthetized by intramuscular (i.m.) injection of a mixture of 5 mg ketamine, 1 mg xylazine, and 0.01 mg atropine per kilogram body weight (BW). For virus inoculation, medical interventions like removal of peripheral lymph nodes, and as premedication for euthanasia, all for which a deeper anesthesia was required, animals were administered i.m. a mixture of 5--10 mg ketamine, 1--2 mg xylazine, and 0.01--0.02 mg atropine per kg BW. At necropsy, animals were euthanized by an overdose of 160--240 mg sodium pentobarbital per kg BW injected into the circulation. Four males and two females were inoculated intravenously with 1 mL of cell-free culture supernatant containing 500 median tissue culture infectious doses of CD3ko-Nef SIV~mac239~. The animals of the other group (five males and one female) received SIV~mac239~ wild-type at the same dose and by the same route as for the mutant virus. Blood samples were collected four to five times before infection, two to three times up to day 7, thereafter at weeks 2, 3, and 4, followed by 2--4-week intervals until 24 weeks post infection (wpi) and thereafter around every 8 weeks until euthanasia because of the development of AIDS-like disease or the end of the study (weeks 82--89). Peripheral lymph nodes were surgically removed once or twice before infection and up to six times between 2 and 66 wpi.

### RNA Purification {#S24}

Total RNA extraction was performed using the Paxgene RNA purification kit (QIAGEN, Hilden, Germany). Briefly, 2.5 ml of whole blood was collected in Paxgene blood RNA tubes and total RNA extraction was performed using the Paxgene RNA purification kit according to manufacturer's specifications; on-column DNase digestion was also performed to remove Genomic DNA. RNA integrity of the extracted RNA was assessed by Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) capillary electrophoresis on a Bioanlayzer RNA nanochip.

### Viral RNA and cell-associated viral load quantitation {#S25}

Viral RNA was extracted from 200 μl plasma using QiaAmp viral RNA isolation mini kit. For qRT-PCR of viral RNA, 8.5 ml RNA-solution were reverse transcribed and amplified using TaKaRa Prime-Script-One-Step-RT-PCR kit (TaKaRa Bio Europe) using primers *gag* forward (5′-ACCCAGTACAACAAATAGGTGGTAACT-3′), *gag* reverse (5′-TCAATTTTACCCAG-GCATTTAATGT-3′) and a fluorescent probe (5′−6FAM(6-carboxyfluorescein)-TGTCCACCT-GCCATTAAGCCCGAG-TAMRA(6-carboxytetramethylrhodamine-3′). Reverse transcription was performed at 45°C for 5 min, amplification was started by an initial denaturation step at 95°C for 10 s, followed by 45 cycles of denaturation for 5 s at 95°C and annealing and elongation at 60°C for 30 s using the Rotor-Gene Q apparatus and software (QIAGEN).

The cell-associated virus load in peripheral blood was determined by a limiting dilution co-cultivation assay as described ([@R65], [@R66]). Instead of testing supernatants of cell cultures for SIV p27, SIV positive cultures were identified by immunoperoxidase staining for intracellular viral proteins with a SIV-hyperimmune serum from an infected macaque as reported ([@R46]). To increase adherence of indicator cells, plates used for staining were coated with Concanavalin A ([@R20]).

### ELISpot assay {#S26}

IFN-γ ELISpots were performed to determine the SIV-specific T cell response in the infected monkeys ([@R68]). For virus-specific stimulation, SIV Gag (EVA7066.1--72), Nef (EVA777) and Tat (EVA7069) peptides, and whole SIVmac251 particles chemically inactivated with aldrithiol-2 (ARP1018.1&2, SIV AT-2) were used essentially as described ([@R51]). All reagents for the T cell ELISpot assay were kindly provided by the Centre for AIDS Reagents (National Institute for Biological Standards and Control), UK.

### B cell ELISpot {#S27}

For the detection of antibody-secreting memory (ASC) B cells PBMCs were seeded in 48-well plates (Greiner Bio-One) at a concentration of 2×10^6^/ml in RPMI1640 supplemented with 10% fetal calf serum and 1% penicillin and 1% streptomycin (complete RPMI) and pre-activated with 10 μg/ml pokeweed mitogen (Sigma), and 5 μg/ml CpG (Cytosin-Phosphat-Guanin) class B ODN 2006 (InvivoGen) for three days. For the B cell ELISpot a commercial kit from Mabtech was used. In short, MultiScreen plates with the Immobilon-P PVDF (Polyvinylidenfluorid) membrane (MSIPS4510, Merck Millipore) were activated with 35% ethanol, and washed five times with distilled water. For the detection of total IgG secreting cells, membranes were coated with an IgG capture antibody (MTl91/145) and for the detection of memory B cells with recombinant SIVgp130 (EVA670, NIBSC). Plates coated with bovine serum albumin (PAN-Biotech) served as negative controls. All plates were incubated at 4°C overnight, subsequently washed with PBS and incubated with complete RPMI for 3 h at 37°C. For detection of total IgG secreting cells 100,000 freshly isolated PBMC were added per well. For detection of memory cells, PBMC stimulated with SIV antigen or kept in the negative control plates were added at a concentration of 200,000 cells per well. Plates were incubated for 20 h at 37°C. Thereafter, plates were washed five times with PBS. Antibodies were detected using biotin-conjugated anti human IgG MT78/145 followed by incubation with streptavidin-alkaline-phosphatase and staining with BCIP/NBT (bromo-chloro-indolyl phosphate/nitro blue tetrazolium chloride) PLUS (Moss) according to standard protocols. For enumeration of spots a Bioreader 6000-V (BIOSYS) was used. To calculate the SIV-specific ASC, total IgG wells were used as positive control after subtracting spots measured in the negative control wells. Memory B cells were defined as the number of ASC after subtraction of spots from the negative controls and expressed as percent of total IgG secreting ASC per 1×10^6^ PBMC.

### Serological testing {#S28}

To analyze for the SIV-specific humoral immune response in blood, a standard ELISA was performed using recombinant SIV p27 (EVA643.2) and SIV gp130 (cat. \# 100841) kindly provided by the Centre for AIDS Reagents (National Institute for Biological Standards and Control), UK. Antigens were coated at 50 ng protein per well. Antibody levels were assessed using 1:200-diluted plasma ([@R67]).

### MHC typing {#S29}

Animals were negative for the major histocompatibility complex (MHC) class I Mamu-A1\*001:01, and -B\*017:01 alleles known to be associated with slow disease progression. Typing was performed as described previously ([@R50]).

### Transcriptome analysis {#S30}

The collection of blood peripheral blood mononuclear cells (PBMC) and peripheral lymph node (LN) samples from wt SIV~mac239~ and CD3ko-Nef infected animals was carried out in two sets. Set A consists of PBMC and LN samples from wt (n = 3) and CD3ko-Nef (n = 3) infected animals at only post-infection time points. There were no LN samples collected at 2 wpi in Set A. In addition to PBMC samples from infected animals, PBMC samples in Set A were also collected from uninfected control animals (n = 10). Set B consists of PBMC and LN samples from wt (n = 3) and CD3ko-Nef (n = 3) infected animals before and after infection.

RNA was extracted from these samples using RNeasy Mini kits (QIAGEN, CA) with DNase digest and QIAcube automation stations. Extracted RNA was quantified using a NanoDrop 2000 spectrophotometer (Thermo Scientific Inc. Wilmington, DE) and the quality was assessed by Bioanalyzer analysis (Agilent Technologies, Santa Clara, CA). For Set A samples, libraries were prepared using the Illumina (Illumina Inc. San Diego, Ca, USA) TruSeq mRNA stranded kit, as per manufacturer's instructions, with 400 ng of total RNA as input. For Set B samples, 10 ng of total RNA was used as input for cDNA amplification using 5′ template-switch PCR with the Clontech SMART-Seq v4 Ultra Low Input RNA kit. Further, for this set, amplified cDNA was fragmented and appended with dual indexed bar codes using Illumina NexteraXT DNA Library Prep kits. The amplified libraries from both sets were validated by capillary electrophoresis on the Agilent 4200 TapeStation. The libraries were normalized, pooled and sequenced on the Illumina HiSeq 3000 system employing a single-end 101 cycles run at average read depths of 16 million reads/sample (Set A) and 25 million reads/sample (Set B).

For further analysis, Set A and B samples were combined. The sequencing data was demultiplexed using Illumina bcl2fastq version 2.20.0.422. The quality of raw reads was assessed with FastQC version 0.11.8 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc>). Reads were mapped to the MacaM version 7 assembly of the Indian rhesus macaque genomic reference ([@R74]) assembly available at: <https://www.unmc.edu/rhesusgenechip/index.htm> RhesusGenome using STAR version 2.5.2b with default alignment parameters ([@R12]). Abundance estimation of raw read counts per transcript was done internally with STAR using the htseq-count algorithm ([@R3]).

DESeq2 version 1.22.1 R package was used to produce normalized read counts and a regularized log expression table ([@R37]). Here, RNA-Seq data analysis was performed separately for the PBMC and LN datasets. Further, DESeq2 was used to compute the differential expression estimation between infected and uninfected samples as well as CD3ko versus wt comparisons at 2 wpi (peak-viremia). PBMC and LN infected datasets consist of samples collected at 2 wpi from wt SIV~mac239~ and CD3ko-Nef infected animals. PBMC uninfected dataset consists of blood samples collected from control animals and those from infected animals at 4 weeks before infection. LN uninfected dataset consists of samples collected from infected animals at 2 weeks before infection.

### Gene set enrichment analysis and heatmaps {#S31}

Gene set enrichment analysis (GSEA) was performed on the PBMC and LN regularized log expression data using the Broad Institute GSEA desktop module (<https://www.broadinstitute.org/gsea/>). Enrichment analysis was performed for CD3ko-Nef versus uninfected, wt versus uninfected and CD3ko-Nef versus wt datasets for PBMC and lymph node samples. Heatmaps were generated to visualize the expression patterns of the leading edge genes in the indicated gene sets for that enrichment analysis. For both the PBMC and LN regularized log expression data, the expression for each gene was normalized by the mean expression across all samples (CD3ko-Nef, wt and uninfected samples). These were then plotted based on a gradient color-scale. The gene sets have been provided in the [Table S1](#SD2){ref-type="supplementary-material"}.

### Multiplex cytokine profile analysis {#S32}

To simultaneously detect various chemokines and cytokines, we performed a multiplex assay as previously described ([@R19]). In brief, we applied the Luminex technology that utilizes combinations of two monoclonal antibodies to identify specific targets; one that captures the target molecule and a second coupled to specific beads directed to a different epitope in the same target, to detect the captured analyte. Subsequent analyses by flow cytometry allows to discriminate between particles on the basis of color and size, enabling simultaneous detection of numerous molecules. We have previously identified reagents that recognize the rhesus macaque homologs of human molecules and allow the identification of multiple monkey cytokines and chemokines in a single test tube ([@R19]; [@R49]). A total of 15 cytokines/chemokines were measured in macaque plasma by Luminex at baseline, days 5, 7, and 10, and weeks 2, 3 4, and 8 post SIV infection. The analytes included: B cell activating factor (BAFF), eotaxin (CCL11), interferon alpha (IFN-α) and gamma (IFN-γ), interleukin-6 (IL-6), IL-8, and IL-12 p40, IL-1 receptor antagonist (IL-1Ra), monokine induced by IFN-gamma (MIG/CXCL9), macrophage inflammatory protein 1-alpha (MIP-1α/CCL3) and beta (MIP-1β/CCL4), C-X-C motif chemokine 10 (CXCL10/IP-10) and 11 (CXCL11/I-TAC), perforin, and tumor necrosis factor-alpha (TNF-α). Only analytes quantifiable above the limit of detection are presented.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S33}
---------------------------------------

Statistical analyses were performed with GraphPad PRISM (GraphPad Software) and Microsoft Excel. P values were calculated using the two-tailed unpaired Student's-t test. Correlations were calculated with the linear regression module. Unless otherwise stated, all experiments were performed three times and the data are shown as mean ± SEM. Significant differences are indicated as: \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001. Statistical parameters are specified in the figure legends.

DATA AND CODE AVAILABILITY {#S34}
--------------------------

RNA-Seq data is available in the Gene Expression Omnibus (GEO) repository under accession number GEO: GSE141626.
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![Specific Disruption of the CD3 Downmodulation Function of SIV~mac239~ Nef\
(A) Overview on the SIV~mac239~ genome and the amino acid changes introduced into the Nef protein.\
(B) Western blot analysis of HEK293T cells transfected with pCG vectors encoding AU1-tagged Nefs followed by an internal ribosome entry site (IRES) element and EGFP. The Nef variants were probed with an anti-AU1 monoclonal antibody. β-Actin and GFP were measured to control for protein quantity and transfection efficiencies, respectively.\
(C) Human PBMCs were transduced with HIV-1 NL4--3 IRES-EGFP constructs expressing the indicated full-length *nef* alleles or a disrupted *nef* gene containing stop signals at codons two and three (*nef*\*) and assayed for surface expression of CD3, CD4, MHC-I, CXCR4, and CD28. Shown are average values + SD derived from three independent experiments. Stars indicate significant difference from WT SIV~mac239~ Nef. \*p \< 0.05; \*\*p \> 0.01; \*\*\*p \< 0.001.\
(D) Infectivity of (left) SIV~mac239~ and (right) HIV-1 NL4--3 variants expressing the indicated Nefs in P4-CCR5 reporter cells. Infections were performed in triplicate with virus stocks containing normalized amounts of p27 or p24 antigen. RLU/s, relative light units per second.\
(E) Percentages of GFP^+^ cells detected in PBMC cultures infected with HIV-1 NL4--3 IRES-EGFP constructs expressing the indicated Nef proteins. Shown are average values derived from three independent infections.\
(F) Analysis of Jurkat cells stably transfected with an NFAT-dependent reporter gene following transduction with the indicated vesicular stomatitis virus G protein (VSV-G) pseudotyped HIV-1 Nef/EGFP constructs and subsequent stimulation with phytohemagglutinin (PHA). Levels of NFAT-dependent luciferase reporter activity are the average (± SD) of triple infections.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1563620-f0002){#F1}

![Importance of Nef-Mediated Downmodulation of CD3-TCR for the Maintenance of High Viral Loads in the SIV~mac~/Macaque Model\
(A) Mean viral RNA loads (± SD) in rhesus macaques infected with WT or CD3ko-Nef SIV~mac239~ constructs (n = 6 per group). The middle and right panels show viral loads in individual animals infected with the WT and CD3ko-Nef SIV~mac239~ constructs, respectively. The detection limit for viral RNA was 40 copies/mL plasma. Plus sign indicates death of the infected animal.\
(B) Alterations in Nef sequences detected in plasma samples obtained from the macaques at the indicated time points. Only the predominant deduced amino acid sequence is shown; X indicates that no amino acid could be clearly assigned. The two amino acid positions involved in CD3 downmodulation are highlighted in yellow and the functionally neutral exchange in gray.\
(C) vRNA loads in animals infected with the CD3ko-Nef SIV~mac239~ construct. Orange symbols indicate partial (i.e., one of the two critical residues), and red symbols indicate complete (i.e., both critical residues) functional reversion.\
(D) Mean vRNA loads (±SEM) in macaques showing rapid or slow/now reversion compared to WT-infected animals. The shaded area indicates the time frame, in which reversions emerged in the "rapid reversion" group of animals.\
(E) Cell-associated viral loads. Shown are the numbers of infectious cells per 1 million PBMC isolated from macaques infected with WT (left) or CD3ko-Nef SIV~mac239~ (right). Symbols are specified in (A) and (C), respectively.\
(F) Mean cell-associated viral loads (±SEM) in macaques showing rapid (red) or slow/no (light blue) reversion compared to WT-infected animals.\
See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1563620-f0003){#F2}

![Lack of Nef-Mediated CD3 Downmodulation Is Associated with Increased Acute Inflammatory Responses\
(A) Top 20 BioCarta, KEGG, and Hallmark pathways enriched in CD3ko-Nef compared to WT SIV~mac239~ infection of rhesus macaques. Pathways involved in intrinsic, innate, or adaptive immunity are highlighted in yellow.\
(B and C) GSEA plots and heatmaps of CD3ko-Nef versus WT in lymph node and PBMC datasets for the (B) inflammatory and (C) restriction factor gene sets. The CD3ko-Nef and WT datasets consist of samples collected at 2 weeks pi from CD3ko-Nef and WT SIV~mac239~-infected animals, respectively. The running enrichment score (y axis) is indicated for each gene ordered by their rank in the whole dataset for that specific comparison (shown by the bars below the x axis). The right panels show heatmaps for the leading-edge genes of the indicated gene sets for PBMC and lymph node (Ln) samples. The color scale is shown at the bottom, with lowest to highest gene expression across all animals represented by the blue to red color gradient\
See also [Figure S3](#SD1){ref-type="supplementary-material"} and [Table S1](#SD2){ref-type="supplementary-material"}.](nihms-1563620-f0004){#F3}

![Expression of Proinflammatory Cytokines in WT and CD3ko-Nef SIV~mac239~ Infection\
(A) Detection of proinflammatory cytokines in plasma of the 12 rhesus macaques infected with WT or CD3ko-Nef SIV~mac239~. Cytokines were measured by Luminex at the indicated time points. The lines indicate mean ± SEM. For IL-6, induction compared to baseline is shown, since the basal levels varied substantially between animals. Asterisks in all panels indicate significant differences between the groups (\*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001).\
(B) Comparison of the average peak levels of the cytokines indicated in (A) between the six animals infected with the CD3ko-Nef construct and macaques infected with WT SIV~mac239~ (set to 100%). In the right panel, cytokine levels were normalized for the corresponding RNA loads prior to comparison between the groups.\
(C) Modulation of the mRNA levels of type I IFNs and other cytokines in lymph nodes and PBMCs isolated from animals infected with WT or CD3ko-Nef SIV~mac239~ constructs.\
See also [Figure S4](#SD1){ref-type="supplementary-material"} and [Table S1](#SD2){ref-type="supplementary-material"}.](nihms-1563620-f0005){#F4}

![Survival and Immunological Outcome in WT and CD3ko-Nef SIV~mac239~ Infection\
(A) Kaplan-Meier survival curves for the indicated groups of SIV-infected macaques with time measured from the date of infection.\
(B and C) Levels of (B) CD4^+^ and (C) CCR5^+^CD4^+^ T cells in blood of infected macaques compared to baseline (100%). The left and middle panels show values obtained for individual animals and the right panels mean values (± SEM) measured for the WT (black) and CD3ko-Nef rapid (red) and no/slow (light blue) revertant groups. In (C), animal 15226 was omitted, because it showed exceedingly high background levels. Asterisks in (B) and (F) indicate significant differences between the no/slow and rapid reverter groups (\*p \< 0.05; \*\*\*p \< 0.001).\
(D and E) IFN-γ ELISpot responses to (D) whole inactivated SIV~mac~ (SIV-AT2) and (E) an SIV Gag peptide pool at the indicated weeks pi. Symbols specifying individual animals are shown in (B).\
(F) B cell ELISpot responses to the SIV~mac~ gp130 external envelope glycoprotein. ASC, antibody secreting cell.\
(G and H) Antibody titers against the (G) SIV-gp130 Env and (H) SIV-p27 capsid proteins determined in serum of animals infected with WT or CD3ko SIV~mac239~ by ELISA (see also [Figure S5](#SD1){ref-type="supplementary-material"}).](nihms-1563620-f0006){#F5}

###### 

Clinical Outcome and Necropsy Findings of WT and CD3ko-Nef SIV~mac239~ Infection

  Animal No.   Nef Phenotype   Reversion or Restoration^[a](#TFN2){ref-type="table-fn"}^   Death (weeks pi)^[b](#TFN3){ref-type="table-fn"}^   Diagnosis and Clinical Signs                                                                                                                            Main Necropsy Findings
  ------------ --------------- ----------------------------------------------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  14892        WT              NA                                                          70                                                  simian AIDS; reduced feed intake 3 days before necropsy, mild diarrhea, moderate to severe anemia by week 60, severe thrombocytopenia before necropsy   erosive-ulcerative transmural jejunitis, multiple extramedullary hematopoiesis foci (indicating impaired hematopoiesis), generalized hyperplasia of lymphatic system
  14893        WT              NA                                                          51                                                  simian AIDS; reduced feed intake for 1 week before necropsy, coughing and dyspnea by week 45, diarrhea by week 50                                       lymphatic system depleted, interstitial pneumonia with intranuclear inclusion bodies, suspect of CMV-induced pneumonia, subacute colitis
  15226        WT              NA                                                          35                                                  simian AIDS; persistent diarrhea by week 25, loss of appetite by week 31                                                                                depletion of lymphatic system, severe chronic-active bacterial and parasitic gastroenteritis induced by protozoa
  2729         WT              NA                                                          89                                                  moderate to severe thrombocytopenia by week 44, otherwise clinically healthy                                                                            chronic endocardiosis of mitral valve, generalized moderate to severe activation of lymphatic system including GALT and BALT system and kidney
  15925        WT              NA                                                          56                                                  simian AIDS; recurrent diarrhea by week 53, reduced appetite shortly before necropsy                                                                    moderate chronic-active gastro-enteritis, generalized activation of the lymphatic system
  15934        WT              NA                                                          33                                                  simian AIDS; mild diarrhea by week 26, moderate amount of stool protozoa, reduced feed intake and dyspnea by week 32                                    severe diffuse pneumocystosis of the lung
  2503         CD3ko           6--12 weeks pi                                              73                                                  simian AIDS; loss of body weight, loss of appetite by week 72, severe diarrhea                                                                          B cell lymphoma in the stomach, T-/B cell lymphoma in pancreoduodenal LN, tumors lymphocryptovirus positive; endoparasitosis of the large intestine by *Trichuris* and *Balantidium spec*.
  2583         CD3ko           8 weeks pi                                                  45                                                  simian AIDS; reduced appetite by week 44, spontaneous death during the night                                                                            B cell lymphoma in the wall of the urinary bladder neck obstructing the ureters, death from uremia, tumor lymphocryptovirus positive
  14875        CD3ko           none                                                        82                                                  clinically healthy                                                                                                                                      none
  2746         CD3ko           12 weeks pi                                                 23                                                  simian AIDS; mild recurrent therapy-resistant diarrhea by week 19, reduced appetite                                                                     moderate chronic-active enteritis, LNs with moderate lymphoid follicular hyperplasia
  15926        CD3ko           partial 52 weeks pi                                         88                                                  clinically healthy                                                                                                                                      generalized mild activation of the lymphatic system
  15899        CD3ko           37--52 weeks pi                                             81                                                  simian AIDS; therapy-resistant watery diarrhea by week 80 with reduced appetite                                                                         moderate chronic-active gastroenteritis combined with multifocal erosive colitis induced by CMV infection, involution of the spleen with depletion of follicles

BALT, bronchus-associated lymphoid tissue; CMV, cytomegalovirus; GALT, gut-associated lymphoid tissue; LN, lymph node; NA, not applicable.

Weeks pi, at which reversion was detected at amino acids positions 123 or 146 until full reversion to the WT *nef* sequence.

Animals were euthanized at the end of the investigation period or when they developed severe SIV-induced immunodeficiency.

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                       SOURCE                                                  IDENTIFIER
  ------------------------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------
  Antibodies                                                                                                                        
  Mouse monoclonal anti-HA tag (HA.C5)                                      Abcam                                                   Cat\# ab18181 RRID:AB_444303
  Mouse monoclonal anti-HIV-1 p24 (39/5.4A)                                 Abcam                                                   Cat\# ab9071 RRID:AB_306981
  Rabbit polyclonal anti-GFP                                                Abcam                                                   Cat\# ab290 RRID:AB_303395
  Rabbit polyclonal anti-AU1 tag                                            Covance                                                 Cat\# MMS-130P RRID:AB_291308
  Mouse monoclonal anti-β-actin                                             Abcam                                                   Cat\# ab8227 RRID:AB_306371
  Rabbit polyclonal anti-GAPDH                                              Biolegend                                               Cat\# 631401 RRID:AB_2247301
  Mouse monoclonal anti-GAPDH                                               Santa Cruz                                              Cat\# sc-365062 RRID:AB_10847862
  Mouse monoclonal anti-CD4, APC conjugated                                 Thermo Fisher                                           Cat\# MHCD0405 RRID:AB_10373698
  Mouse monoclonal anti-HIV-1 core, FITC conjugated                         Beckman Coulter                                         Cat\# 6604665 RRID:AB_1575987
  Mouse monoclonal anti-CD4, APC conjugated                                 Thermo Fisher                                           Cat\# MHCD0405 RRID:AB_10373698
  Mouse anti-human CD4 APC (clone RPA-T4)                                   BD Biosciences                                          Cat\# 555349 RRID: AB_398593
  Mouse anti-human CD28 PE (clone L293)                                     BD Biosciences                                          Cat\# 348047 RRID: AB_400368
  Mouse anti-human MHCI APC (clone W6/32)                                   BioLegend                                               Cat\# 311410 RRID: AB_314879
  Mouse anti-human, baboon, cynomolgus, rhesus CD3 V450 (clone SP34--2)     BD Biosciences                                          Cat\# 560351 RRID: AB_1645168
  Mouse anti-human CXCR4 APC (clone 12G5)                                   BD Biosciences                                          Cat\# 555976 RRID: AB_398616
  Mouse anti-human CXCR4 APC (clone 12G5)                                   BD Biosciences                                          Cat\# 555976 RRID: AB_398616
  Mouse anti-human, rhesus, cynomolgus, baboon MHCI PE (clone G46--2.6)     BD Biosciences                                          Cat\# 555553 RRID: AB_395936
  Mouse anti-human, baboon, cynomolgus, rhesus CD3 PE-Cy7 (clone SP34--2)   BD Biosciences                                          Cat\# 557749 RRID: AB_396855
  Mouse anti-human, baboon, cynomolgus, rhesus CD4 APC-H7 (clone L200)      BD Biosciences                                          Cat\# 560837 RRID: AB_10563933
  Mouse Anti-NHP CD45 (clone D058--1283)                                    BD Biosciences                                          Cat\# 561489 RRID:AB_10683313
  Mouse Anti-Human CD195 (clone 3A9, PE)                                    BD Biosciences                                          Cat\# 556042 RRID:AB_396313
  CD8 Mouse anti-Human (Clone: 3B5)                                         Invitrogen                                              Cat\# 11320782 RRID:AB_1484754
  CD8 antibody (RPA-T8)                                                     BioLegend                                               Cat\# 301024 RRID:AB_2561282
  Anti-human CD20 Antibody (2H7)                                            BioLegend                                               Cat\# 302301 RRID:AB_314249
  Anti-human CD25 Antibody (M-A251)                                         BioLegend                                               Cat\# 356101 RRID:AB_2561751
  Anti-human HLA-DR Antibody (L243)                                         BioLegend                                               Cat\# 307602 RRID:AB_314680
  Mouse anti-human BST2 APC (clone RS38E)                                   BioLegend                                               Cat\# 348410 RRID: AB_2067121
  Anti-human CD69 Antibody (clone TP1.55.3)                                 Beckman Coulter                                         Cat\# 6607110 RRID:AB_1575978
  Bacterial and Virus Strains                                                                                                       
  *Escherichia coli* XL-2 blue                                              Stratagene                                              Cat\# 200150
  XL2-Blue MRF' TM Ultracompetent cells                                     Agilent Technologies                                    Cat\# 200151
  Biological Samples                                                                                                                
  Human: Peripheral blood mononuclear cells                                 DRK-Blutspende-dienst Baden-Wurttemberg, Ulm, Germany   N/A
  Chemicals, Peptides, and Recombinant Proteins                                                                                     
  L-Glutamine                                                               Pan Biotech                                             Cat\# P04--80100
  Penicillin-Streptomycin                                                   ThermoFisher                                            Cat\# 15140122
  Biocoll separating solution                                               Biochrom                                                Cat\# L6115
  Lymphoprep                                                                Stemcell                                                Cat\# 07851
  Phorbol 12-myristate 13-acetate (PMA)                                     Sigma-Aldrich                                           Cat\# 79346
  Lipofectamine RNAiMAX Transfection Reagent                                ThermoFisher                                            Cat\# 13778150
  TransIT®-LT1 Transfection Reagent                                         Mirus                                                   Cat\# MIR 2305
  β-mercaptoethanol                                                         Sigma Aldrich                                           Cat\# M6250--100ML
  HIV-1 p24 protein (ELISA standard)                                        Abcam                                                   Cat\# 43037
  KPL SureBlue TMB Microwell Peroxidase Substrate                           Medac                                                   Cat\# 52-00-04
  4X Protein Sample Loading Buffer                                          LI-COR                                                  Cat\# 928--40004
  2-Mercaptoethanol                                                         Sigma-Aldrich                                           Cat\# M6250--100ML
  NucRed Live 647 ReadyProbes Reagent                                       ThermoFisher                                            Cat\# R37106
  Fixable Viability Dye eFluor 450                                          eBioscience                                             Cat\# 65-0863-14
  Critical Commercial Assays                                                                                                        
  RosetteSep Human CD4+ T Cell Enrichment Cocktail                          Stem Cell Technologies                                  Cat\# 15062
  EasySep Human Naive CD4+ T Cell Isolation Kit                             Stemcell                                                Cat\# 19555
  QuikChange II XL Site-Directed Mutagenesis Kit                            Agilent                                                 Cat\# 200522
  Phusion High-Fidelity PCR Kit                                             ThermoFisher                                            Cat\# F553L
  DNA Ligation Kit Ver. 2.1                                                 TaKaRa                                                  Cat\# 6022
  GalScreen                                                                 Applied Bioscience                                      Cat\# T1027
  RNeasy Plus Mini Kit                                                      QIAGEN                                                  Cat\# 74136
  GAPDH Endogenous Control (VIC/TAMRA)                                      ThermoFisher                                            Cat\# 4310884E
  Luciferase Cell Culture Lysis 5X Reagent                                  Promega                                                 Cat\# E1531
  Luciferase Assay System 10-pack                                           Promega                                                 Cat\# E1501
  Deposited Data                                                                                                                    
  RNA-seq data                                                              Gene Expression Omnibus (GEO) repository                Accession number GSE141626
  Experimental Models: Cell Lines                                                                                                   
  Human: HEK293T cells                                                      ATCC                                                    Cat\# CRL-3216 RRID: CVCL_0063
  Human: TZM-bl cells                                                       NIH AIDS Reagent Program                                Cat\# 8129 RRID: CVCL_B478
  P4 MAGI CCR5+ Cells                                                       NIH AIDS Reagent Program                                Cat\# 3580
  Jurkat NFAF-Luc cells                                                     [@R17]                                                  N/A
  Experimental Models: Organisms/Strains                                                                                            
  Rhesus macaques                                                           German Primate Center                                   N/A
  Recombinant DNA                                                                                                                   
  Plasmid: pCMV-VSV-G                                                       Addgene                                                 Cat\# 8454
  Plasmid: p99 PUR RPS EGFP                                                 John L. Goodier                                         N/A
  Plasmid: p99 JM111 EGFP                                                   John L. Goodier                                         N/A
  Plasmid: pL1RP-luc                                                        Gerald Schumann                                         N/A
  Plasmid: pBR322_SIVmac 239                                                F. Kirchhoff (Ulm University)                           N/A
  Plasmid: pCMV-VSV-G                                                       Addgene                                                 Cat\# 8454
  Software and Algorithms                                                                                                           
  BD FACSDiva Version 8.0                                                   BD Biosciences                                          <https://www.bdbiosciences.com/en-us> RRID: SCR_001456
  Corel DRAW 2017                                                           Corel Corporation                                       <https://www.coreldraw.com/en/>
  GraphPad Prism Version 7                                                  GraphPad Software, Inc.                                 <https://www.graphpad.com> RRID: SCR_002798
  ImageJ                                                                    Open source                                             <https://imagej.nih.gov/ij/>
  LI-COR Image Studio Lite Version 5.0                                      LI-COR                                                  <https://www.licor.com/> RRID : SCR_013715

###### Highlights

-   Mutation of I123L and L146F specifically disrupts CD3 downmodulation by SIV~mac~ Nef

-   Lack of CD3 modulation by Nef increases the inflammatory response to SIV infection

-   Increased immune activation aggravates the course of infection if SIV evades control

-   Nef-mediated CD3 downmodulation seems critical for effective immune evasion of SIV
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